Viking Therapeutics (NASDAQ: VKTX) is emerging as a potential disruptor in the GLP-1 market, traditionally dominated by giants Novo Nordisk and Eli Lilly. With its VK2735 candidate currently in phase 3 clinical trials, Viking is positioned to capitalize on the estimated $100 billion GLP-1 weight loss market. The promising results from earlier trials suggest significant upside potential, especially if the oral version of VK2735 proves viable.

The stakes are high for Viking, as the success of VK2735 could lead to a dramatic surge in its stock price, potentially making it an attractive acquisition target. Conversely, disappointing trial results could severely impact its market valuation, which currently stands at around $4 billion. Given the volatility and binary nature of this investment, market professionals should approach with caution, sizing positions appropriately.

For investors, Viking Therapeutics represents a high-risk, high-reward opportunity within the biotech sector, with the next few months likely to be crucial for its future trajectory.

Source: fool.com